Day One Biopharmaceuticals (DAWN) Stock Forecast, Price Target & Predictions
DAWN Stock Forecast
Day One Biopharmaceuticals stock forecast is as follows: an average price target of $24.00 (represents a 89.42% upside from DAWN’s last price of $12.67) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
DAWN Price Target
The average price target for Day One Biopharmaceuticals (DAWN) is $24.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $24.00. This represents a potential 89.42% upside from DAWN's last price of $12.67.
DAWN Analyst Ratings
According to 5 Wall Street analysts, Day One Biopharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for DAWN stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Day One Biopharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 01, 2024 | Alec Stranahan | Bank of America Securities | $24.00 | $14.31 | 67.71% | 89.42% |
| May 07, 2024 | Andrew Maldonado | H.C. Wainwright | $40.00 | $16.60 | 140.96% | 215.71% |
| Jan 08, 2023 | Joseph Catanzaro | Piper Sandler | $45.00 | $21.34 | 110.87% | 255.17% |
| Dec 15, 2022 | H.C. Wainwright | $35.00 | $21.61 | 61.96% | 176.24% | |
| Dec 14, 2022 | Needham | $40.00 | $20.53 | 94.84% | 215.71% | |
| Dec 05, 2022 | Goldman Sachs | $45.00 | $21.74 | 106.99% | 255.17% | |
| Jun 20, 2022 | Joseph Catanzaro | Piper Sandler | $40.00 | $15.79 | 153.32% | 215.71% |
The latest Day One Biopharmaceuticals stock forecast, released on Aug 01, 2024 by Alec Stranahan from Bank of America Securities, set a price target of $24.00, which represents a 67.71% increase from the stock price at the time of the forecast ($14.31), and a 89.42% increase from DAWN last price ($12.67).
Day One Biopharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $32.00 |
| Last Closing Price | $12.67 | $12.67 | $12.67 |
| Upside/Downside | -100.00% | -100.00% | 152.57% |
In the current month, the average price target of Day One Biopharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Day One Biopharmaceuticals's last price of $12.67. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 31, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 08, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jan 08, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 14, 2022 | Needham | Buy | Initialise | |
| Dec 05, 2022 | Goldman Sachs | Buy | Initialise | |
| Jun 20, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Day One Biopharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 31, 2024. The company gave DAWN a "Buy" rating, the same as its previous rate.
Day One Biopharmaceuticals Financial Forecast
Day One Biopharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $93.76M | $93.76M | $93.76M | $93.76M | $52.86M | $46.15M | $39.01M | $32.44M | $27.18M | $28.48M | $1.03M |
| High Forecast | $98.36M | $98.36M | $98.36M | $98.36M | $55.46M | $48.41M | $40.92M | $33.28M | $28.73M | $29.88M | $1.03M |
| Low Forecast | $87.80M | $87.80M | $87.80M | $87.80M | $49.50M | $43.21M | $36.53M | $31.67M | $24.60M | $26.67M | $1.03M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Day One Biopharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. DAWN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Day One Biopharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict DAWN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Day One Biopharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Day One Biopharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-37.91M | $-36.54M | $-33.77M | $-32.39M | $-14.06M | $-20.36M | $-24.96M | $-30.78M | $-44.83M | $-30.59M | $-72.78M |
| High Forecast | $-34.78M | $-33.52M | $-30.97M | $-29.71M | $-12.89M | $-18.67M | $-22.90M | $-27.89M | $-31.38M | $-28.06M | $-66.77M |
| Low Forecast | $-40.33M | $-38.88M | $-35.92M | $-34.46M | $-14.95M | $-21.66M | $-26.55M | $-33.66M | $-104.01M | $-32.54M | $-77.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Day One Biopharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DAWN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Day One Biopharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Day One Biopharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to DAWN last annual SG&A of $NaN (undefined).
Day One Biopharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.39 | $-0.38 | $-0.35 | $-0.33 | $-0.14 | $-0.21 | $-0.26 | $-0.32 | $-0.46 | $-0.32 | $-0.75 |
| High Forecast | $-0.36 | $-0.35 | $-0.32 | $-0.31 | $-0.13 | $-0.19 | $-0.24 | $-0.29 | $-0.32 | $-0.29 | $-0.69 |
| Low Forecast | $-0.42 | $-0.40 | $-0.37 | $-0.36 | $-0.15 | $-0.22 | $-0.27 | $-0.35 | $-1.07 | $-0.34 | $-0.80 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Day One Biopharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DAWN previous annual EPS of $NaN (undefined).
Day One Biopharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.58 | $3.67 | 532.76% | Buy |
| PDSB | PDS Bio | $1.64 | $9.00 | 448.78% | Buy |
| INZY | Inozyme Pharma | $2.93 | $16.00 | 446.08% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.79 | $7.00 | 291.06% | Buy |
| TERN | Terns Pharmaceuticals | $5.80 | $18.67 | 221.90% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.67 | $24.00 | 89.42% | Buy |
| MREO | Mereo BioPharma Group | $3.81 | $6.75 | 77.17% | Buy |
| HOOK | HOOKIPA Pharma | $1.90 | $3.00 | 57.89% | Buy |